TECX: Tectonic Therapeutic Inc. Average Forecast Price

Corporate company logo of Tectonic (TECX)

Investors face serious regulatory threats and potential liquidity shortages due to the early stage of testing. However, developing treatments for hard-to-reach protein targets could secure market dominance for Tectonic Therapeutic, Inc. (TECX). This daily price action, where the consensus forecast is set at 70.95, is illustrated below. Future financial success for the business will rely on the commercial launch of therapy based on the G-protein platform.

TECX Tectonic: Consensus Target in the range 06/22/2024 - 11/12/2026
Flagship merchandise of Tectonic Therapeutic

The development of innovative protein therapies in the US directly impacts the aggregate target price of Tectonic Therapeutic, Inc. (TECX), reflecting market expectations for the company's breakthrough biological targets. The current value of 70.95 represents a weighted average expert target that filters out volatility by measuring fundamental value potential against operational risks, allowing investors to objectively assess the asset's degree of overheating.

Competitors of Tectonic Therapeutic, Inc.

Analyst Forecast Prices HLN|Analyst Consensus Forecast KVUE (Kenvue)|Verona Pharma PLC (VRNA) - Average Forecast Price|Jyong Biotech Corp - Analyst Consensus Forecast|Ligand Corp (LGND) - Consensus Target|AMRX (Amneal Pharmaceuticals) - Consensus Target|Broker Consensus Forecast PRGO|Price Target Chart Alvotech SA|Liquidia Corp - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals Corp) - Fair Value Consensus|Analyst Consensus Forecast MNKD (MannKind Corporation)|Analyst Consensus Forecast amphastar.com AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price Target Chart|Consensus Target Aquestive Corp|SCPH (scPharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast tonixpharma.com|Consensus Target SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Fair Value Consensus|Price Target Chart BioHarvest BHST|Invizyne (EXOZ) - Average Forecast Price|ORMP: Consensus Target|Entera Bio Ltd. - Analyst Forecast Prices|HYFT: Analyst Consensus Forecast|ABVC BioPharma Inc. - Fair Value Consensus|CPIX (Cumberland Pharma) - Analyst Consensus Forecast|Average Forecast Price Quantum BioPharma Corp QNTM|Price Target Chart FibroGen, Inc. (FGEN)|TELO (telomirpharma.com) - Fair Value Consensus|Rani Therapeutics Holdings, Inc. - Consensus Target|Analyst Forecast Prices SNYR (Synergy CHC Corp.)|Rallybio Corp. - Analyst Consensus Forecast|Average Forecast Price Lexaria Bioscience|PULM: Analyst Consensus Forecast|Consensus Target Pheton Holdings|Consensus Target APM|LYRA (Lyra Therapeutics Inc.) - Analyst Forecast Prices|Price Target Chart Impact BioMedical Inc (IBO)|TNFA - Average Forecast Price|Price Target Chart cbdMD YCBD|PRFX: Broker Consensus Forecast|Auris Medical - Analyst Consensus Forecast|Analyst Median Target Lipella Pharmaceuticals Inc LIPO|OPTN: Analyst Consensus Forecast|Consensus Target Pieris Pharma|Consensus Target PROC|PTPI: Fair Value Consensus|Consensus Target QLI (Qilian International Holding)|Analyst Forecast Prices SLRN|Analyst Consensus Forecast TFFP (TFF Pharma)